Vaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. decreased its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 10.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,274 shares of the company’s stock after selling 393 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Vaxcyte were worth $374,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. China Universal Asset Management Co. Ltd. boosted its holdings in Vaxcyte by 68.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 21,466 shares of the company’s stock worth $2,453,000 after buying an additional 8,685 shares during the last quarter. Harbor Capital Advisors Inc. boosted its stake in shares of Vaxcyte by 392.4% in the second quarter. Harbor Capital Advisors Inc. now owns 40,342 shares of the company’s stock worth $3,046,000 after acquiring an additional 32,149 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Vaxcyte by 18.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,176,181 shares of the company’s stock worth $216,966,000 after purchasing an additional 498,359 shares in the last quarter. Russell Investments Group Ltd. acquired a new position in Vaxcyte in the 1st quarter valued at $1,288,000. Finally, Tri Locum Partners LP purchased a new position in Vaxcyte in the 2nd quarter worth approximately $8,559,000. Institutional investors and hedge funds own 96.78% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on PCVX shares. Jefferies Financial Group upped their price target on Vaxcyte from $108.00 to $129.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. BTIG Research raised their target price on Vaxcyte from $98.00 to $160.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Bank of America lifted their price target on shares of Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a research report on Wednesday, September 4th. Leerink Partners increased their price objective on Vaxcyte from $106.00 to $153.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 3rd. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Vaxcyte currently has an average rating of “Buy” and an average target price of $147.50.

Insiders Place Their Bets

In related news, CEO Grant Pickering sold 2,366 shares of the business’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $103.89, for a total transaction of $245,803.74. Following the completion of the transaction, the chief executive officer now directly owns 137,398 shares of the company’s stock, valued at $14,274,278.22. The trade was a 1.69 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Andrew Guggenhime sold 8,000 shares of the stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $115.94, for a total value of $927,520.00. Following the completion of the sale, the chief financial officer now directly owns 90,383 shares in the company, valued at $10,479,005.02. This represents a 8.13 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 117,464 shares of company stock worth $12,640,276 over the last three months. Company insiders own 3.10% of the company’s stock.

Vaxcyte Stock Performance

NASDAQ:PCVX opened at $87.08 on Wednesday. Vaxcyte, Inc. has a fifty-two week low of $48.24 and a fifty-two week high of $121.06. The company has a 50 day moving average price of $109.51 and a 200 day moving average price of $89.13. The stock has a market capitalization of $10.85 billion, a P/E ratio of -18.93 and a beta of 1.01.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.27. During the same period last year, the firm earned ($0.91) earnings per share. Research analysts forecast that Vaxcyte, Inc. will post -4.14 earnings per share for the current fiscal year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.